Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 08/29 10:00:00 pm
107.95 USD   -0.77%
08/29 CELGENE CORPORA : to Webcast at Upcoming Investor Conferences and R&..
08/17 CELGENE : Olympic Swimmer and Author Dara Torres Teams Up With Celge..
08/15 CELGENE : Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Offic..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CEST
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
08/29 CELGENE CORPORATION : to Webcast at Upcoming Investor Conferences and R&D Deep D..
08/18 CELGENE : Patent Issued for Mutant-Selective EGFR Inhibitors and Uses (USPTO 940..
08/17 CELGENE : Olympic Swimmer and Author Dara Torres Teams Up With Celgene to Launch..
08/15 CELGENE : Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgen..
08/05 BETTERINVESTING : Magazine Releases October Stock To Study And Undervalued Stock..
08/04 CELGENE : and LYSARC Provide Update on the Phase III 'REMARC' Study of REVLIMID®..
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28 CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/25 Siponimod Rides To Novartis' Rescue
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
08/24 INSIDERINSIGHTS.COM DAILY ROUND UP 8 : Advance Auto Parts, Flowers Foods, AC Con..
08/23 Who's Next After Medivation?
08/23 Janssen submits application in Europe for expanded use of Darzalex
Advertisement
Financials ($)
Sales 2016 11 080 M
EBIT 2016 5 779 M
Net income 2016 3 415 M
Debt 2016 7 253 M
Yield 2016 -
P/E ratio 2016 26,90
P/E ratio 2017 19,06
EV / Sales 2016 8,21x
EV / Sales 2017 6,76x
Capitalization 83 674 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-9.86%83 674
AMGEN, INC.5.66%128 351
GILEAD SCIENCES, INC.-22.75%103 158
REGENERON PHARMACEUTIC..-26.43%42 053
VERTEX PHARMACEUTICALS..-22.96%24 020
ACTELION LTD17.62%18 227
More Results